Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting ...Middle East

HONG KONG, Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific...

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting )

Also on site :

• 'Law & Order's Mariska Hargitay Celebrates Landmark Accomplishment
• Disneyland raises hopes for future Toy Story Midway Mania makeovers
• Thumbprint on cigarette carton leads to arrest in 1977 death of young woman